Literature DB >> 14662904

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

Peifang Sun1, Robert Schwenk, Katherine White, Jose A Stoute, Joe Cohen, W Ripley Ballou, Gerald Voss, Kent E Kester, D Gray Heppner, Urszula Krzych.   

Abstract

The Plasmodium falciparum circumsporozoite (CS) protein-based pre-erythrocytic stage vaccine, RTS,S, induces a high level of protection against experimental sporozoite challenge. The immune mechanisms that constitute protection are only partially understood, but are presumed to rely on Abs and T cell responses. In the present study we compared CS protein peptide-recalled IFN-gamma reactivity of pre- and RTS,S-immune lymphocytes from 20 subjects vaccinated with RTS,S. We observed elevated IFN-gamma in subjects protected by RTS,S; moreover, both CD4(+) and CD8(+) T cells produced IFN-gamma in response to CS protein peptides. Significantly, protracted protection, albeit observed only in two of seven subjects, was associated with sustained IFN-gamma response. This is the first study demonstrating correlation in a controlled Plasmodia sporozoite challenge study between protection induced by a recombinant malaria vaccine and Ag-specific T cell responses. Field-based malaria vaccine studies are in progress to validate the establishment of this cellular response as a possible in vitro correlate of protective immunity to exo-erythrocytic stage malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662904     DOI: 10.4049/jimmunol.171.12.6961

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  104 in total

1.  Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.

Authors:  Y Li; K Svehla; N L Mathy; G Voss; J R Mascola; R Wyatt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Authors:  Sandra A Calarota; Anlan Dai; Jeffrey N Trocio; David B Weiner; Franco Lori; Julianna Lisziewicz
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

3.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Clinical Trials Report: Progress Toward an Effective Malaria Vaccine: RTS,S/ASO1B and RTS,S/ASO2A.

Authors:  Lin H Chen
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

5.  Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivo.

Authors:  Jennifer E Lykens; Catherine E Terrell; Erin E Zoller; Senad Divanovic; Aurelien Trompette; Christopher L Karp; Julio Aliberti; Matthew J Flick; Michael B Jordan
Journal:  J Immunol       Date:  2009-12-14       Impact factor: 5.422

6.  Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria.

Authors:  Chandy C John; Ann M Moormann; Peter O Sumba; Ayub V Ofulla; Daniel C Pregibon; James W Kazura
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Tomatine adjuvantation of protective immunity to a major pre-erythrocytic vaccine candidate of malaria is mediated via CD8+ T cell release of IFN-gamma.

Authors:  Karen G Heal; Andrew W Taylor-Robinson
Journal:  J Biomed Biotechnol       Date:  2010-03-11

8.  T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution?

Authors:  Amadu Jalloh; Muctarr Jalloh; Hiroyuki Matsuoka
Journal:  Malar J       Date:  2009-06-05       Impact factor: 2.979

9.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

10.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.